Trade Biogaia B - BIOGb CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
Spread | 2.1 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.021941% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | -0.000281% | ||||||||
Overnight fee time | 21:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | SEK | ||||||||
Margin | 5% | ||||||||
Stock exchange | Sweden | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
Biogaia AB ESG Risk Ratings
‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.
Prev. Close* | 133.1 |
Open* | 128.8 |
1-Year Change* | 37.75% |
Day's Range* | 123.2 - 128.8 |
52 wk Range | 87.95-119.40 |
Average Volume (10 days) | 73.70K |
Average Volume (3 months) | 2.10M |
Market Cap | 10.31B |
P/E Ratio | 24.47 |
Shares Outstanding | 100.98M |
Revenue | 1.27B |
EPS | 4.33 |
Dividend (Yield %) | 2.73585 |
Beta | 0.57 |
Next Earnings Date | Feb 7, 2024 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Mar 28, 2024 | 124.1 | -5.6 | -4.32% | 129.7 | 130.3 | 120.7 |
Mar 27, 2024 | 133.1 | 0.2 | 0.15% | 132.9 | 134.7 | 131.4 |
Mar 26, 2024 | 132.2 | 1.3 | 0.99% | 130.9 | 132.9 | 130.8 |
Mar 25, 2024 | 132.3 | 2.9 | 2.24% | 129.4 | 132.8 | 129.4 |
Mar 22, 2024 | 128.9 | 0.9 | 0.70% | 128.0 | 129.4 | 126.8 |
Mar 21, 2024 | 128.1 | 1.4 | 1.10% | 126.7 | 130.2 | 126.1 |
Mar 20, 2024 | 124.3 | -1.0 | -0.80% | 125.3 | 126.8 | 123.9 |
Mar 19, 2024 | 125.4 | 0.5 | 0.40% | 124.9 | 125.8 | 123.9 |
Mar 18, 2024 | 125.1 | -1.8 | -1.42% | 126.9 | 126.9 | 124.5 |
Mar 15, 2024 | 125.5 | 0.3 | 0.24% | 125.2 | 128.5 | 124.6 |
Mar 14, 2024 | 126.1 | -0.1 | -0.08% | 126.2 | 127.1 | 125.3 |
Mar 13, 2024 | 125.7 | 1.9 | 1.53% | 123.8 | 126.6 | 121.6 |
Mar 12, 2024 | 125.3 | 0.9 | 0.72% | 124.4 | 126.2 | 120.6 |
Mar 11, 2024 | 123.3 | -3.5 | -2.76% | 126.8 | 127.9 | 122.9 |
Mar 8, 2024 | 128.1 | 1.8 | 1.43% | 126.3 | 128.5 | 125.4 |
Mar 7, 2024 | 126.5 | 0.0 | 0.00% | 126.5 | 128.9 | 126.5 |
Mar 6, 2024 | 129.9 | 0.5 | 0.39% | 129.4 | 131.4 | 127.8 |
Mar 5, 2024 | 131.2 | 2.1 | 1.63% | 129.1 | 132.7 | 128.3 |
Mar 4, 2024 | 129.0 | -0.5 | -0.39% | 129.5 | 131.4 | 128.2 |
Mar 1, 2024 | 129.4 | 2.9 | 2.29% | 126.5 | 129.4 | 125.3 |
Biogaia B Events
Time (UTC) | Country | Event |
---|---|---|
Tuesday, May 7, 2024 | ||
Time (UTC) 06:00 | Country SE
| Event Q1 2024 Biogaia AB Earnings Release Q1 2024 Biogaia AB Earnings ReleaseForecast -Previous - |
Sunday, July 7, 2024 | ||
Time (UTC) 06:00 | Country SE
| Event Q2 2024 Biogaia AB Earnings Release Q2 2024 Biogaia AB Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total revenue | 1103.96 | 785.11 | 747.077 | 768.347 | 741.87 |
Revenue | 1103.96 | 785.11 | 747.077 | 768.347 | 741.87 |
Cost of Revenue, Total | 302.028 | 202.161 | 200.159 | 204.349 | 185.956 |
Gross Profit | 801.929 | 582.949 | 546.918 | 563.998 | 555.914 |
Total Operating Expense | 742.498 | 531.373 | 518.927 | 525.836 | 464.511 |
Selling/General/Admin. Expenses, Total | 358.26 | 233.221 | 196.289 | 207.058 | 179.783 |
Research & Development | 103.977 | 102.865 | 102.84 | 103.164 | 98.776 |
Depreciation / Amortization | 5.184 | 4.364 | 3.296 | 3.765 | 1.945 |
Interest Expense (Income) - Net Operating | -26.792 | -11.506 | 0 | -6.504 | |
Operating Income | 361.459 | 253.737 | 228.15 | 242.511 | 277.359 |
Interest Income (Expense), Net Non-Operating | 86.154 | -1.025 | -0.567 | -0.252 | 0.641 |
Other, Net | -0.405 | ||||
Net Income Before Taxes | 447.613 | 252.712 | 227.583 | 242.259 | 277.595 |
Net Income After Taxes | 373.773 | 196.273 | 179.73 | 187.258 | 214.233 |
Minority Interest | 0 | 0 | 0 | 0.089 | 0.657 |
Net Income Before Extra. Items | 373.773 | 196.273 | 179.73 | 187.347 | 214.89 |
Total Extraordinary Items | |||||
Net Income | 373.773 | 196.273 | 179.73 | 187.347 | 214.89 |
Income Available to Common Excl. Extra. Items | 373.773 | 196.273 | 179.73 | 187.347 | 214.89 |
Income Available to Common Incl. Extra. Items | 373.773 | 196.273 | 179.73 | 187.347 | 214.89 |
Diluted Net Income | 373.773 | 196.273 | 179.73 | 187.347 | 214.89 |
Diluted Weighted Average Shares | 100.982 | 100.963 | 89.2403 | 86.68 | 86.68 |
Diluted EPS Excluding Extraordinary Items | 3.70138 | 1.944 | 2.014 | 2.16136 | 2.47912 |
Dividends per Share - Common Stock Primary Issue | 2.9 | 1.452 | 1.364 | 1.6 | 2 |
Diluted Normalized EPS | 3.74232 | 2.07652 | 2.014 | 2.16136 | 2.47912 |
Other Operating Expenses, Total | 0 | 0.366 | 16.343 | 7.5 | 4.555 |
Unusual Expense (Income) | -0.159 | -0.098 |
Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
---|---|---|---|---|---|
Total revenue | 317.694 | 315.217 | 365.821 | 274.283 | 257.733 |
Revenue | 317.694 | 315.217 | 365.821 | 274.283 | 257.733 |
Cost of Revenue, Total | 81.847 | 88.779 | 103.309 | 66.291 | 71.952 |
Gross Profit | 235.847 | 226.438 | 262.512 | 207.992 | 185.781 |
Total Operating Expense | 198.156 | 220.18 | 217.823 | 203.157 | 163.998 |
Selling/General/Admin. Expenses, Total | 96.002 | 101.045 | 97.887 | 101.961 | 84.578 |
Research & Development | 20.63 | 38.816 | 18.684 | 31.431 | 22.557 |
Other Operating Expenses, Total | -0.323 | -8.46 | -2.057 | 3.474 | -15.089 |
Operating Income | 119.538 | 95.037 | 147.998 | 71.126 | 93.735 |
Interest Income (Expense), Net Non-Operating | 8.484 | 7.023 | 2.563 | 81.323 | 5.066 |
Net Income Before Taxes | 128.022 | 102.06 | 150.561 | 152.449 | 98.801 |
Net Income After Taxes | 101.501 | 80.547 | 115.945 | 139.428 | 79.503 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Net Income Before Extra. Items | 101.501 | 80.547 | 115.945 | 139.428 | 79.503 |
Net Income | 101.501 | 80.547 | 115.945 | 139.428 | 79.503 |
Income Available to Common Excl. Extra. Items | 101.501 | 80.547 | 115.945 | 139.428 | 79.503 |
Income Available to Common Incl. Extra. Items | 101.501 | 80.547 | 115.945 | 139.428 | 79.503 |
Diluted Net Income | 101.501 | 80.547 | 115.945 | 139.428 | 79.503 |
Diluted Weighted Average Shares | 100.982 | 100.982 | 100.982 | 100.982 | 100.982 |
Diluted EPS Excluding Extraordinary Items | 1.00514 | 0.79764 | 1.14817 | 1.38072 | 0.7873 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 2.9 | 0 |
Diluted Normalized EPS | 1.00514 | 0.80747 | 1.14817 | 1.39612 | 0.7873 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total Current Assets | 1797.48 | 1752.08 | 1689.58 | 452.438 | 494.415 |
Cash and Short Term Investments | 1488.37 | 1484.68 | 1467.88 | 218.814 | 289.794 |
Cash & Equivalents | 1488.37 | 1484.68 | 1467.88 | 213.831 | 284.962 |
Short Term Investments | 0 | 4.983 | 4.832 | ||
Total Receivables, Net | 149.455 | 148.53 | 143.196 | 156.316 | 154.819 |
Accounts Receivable - Trade, Net | 131.054 | 128.152 | 101.658 | 129.763 | 142.009 |
Total Inventory | 142.838 | 102.737 | 72.277 | 68.445 | 44.213 |
Prepaid Expenses | 1.872 | 0 | 1.735 | 1.731 | 1.477 |
Other Current Assets, Total | 14.95 | 16.13 | 4.486 | 7.132 | 4.112 |
Total Assets | 2213.97 | 2128.05 | 1913.28 | 665.9 | 659.973 |
Property/Plant/Equipment, Total - Net | 157.725 | 153.635 | 162.765 | 149.042 | 105.935 |
Property/Plant/Equipment, Total - Gross | 301.359 | 275.996 | 256.218 | 218.949 | 166.773 |
Accumulated Depreciation, Total | -143.634 | -122.361 | -93.453 | -69.909 | -60.84 |
Intangibles, Net | 46.075 | 48.086 | 50.322 | 52.558 | 45.85 |
Long Term Investments | 25.843 | 22.272 | 0.039 | 0.044 | 0.043 |
Other Long Term Assets, Total | 15.325 | 2.757 | 5.279 | 6.518 | 8.43 |
Total Current Liabilities | 164.991 | 126.954 | 135.062 | 124.8 | 145.173 |
Accounts Payable | 32.05 | 42.313 | 48.046 | 28.491 | 34.009 |
Accrued Expenses | 77.945 | 56.399 | 48.723 | 53.913 | 57.349 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 43.896 | 19.342 | 30.093 | 34.83 | 53.815 |
Total Liabilities | 241.55 | 250.689 | 167.039 | 158.028 | 154.991 |
Total Long Term Debt | 0 | 10.4 | 20.7 | 17.254 | 0 |
Deferred Income Tax | 12.552 | 14.24 | 11.312 | 10.339 | 6.679 |
Minority Interest | 0.002 | 0.002 | 0.002 | 0.002 | 3.139 |
Total Equity | 1972.42 | 1877.36 | 1746.24 | 507.872 | 504.982 |
Common Stock | 20.196 | 20.196 | 20.196 | 17.336 | 17.336 |
Additional Paid-In Capital | 1153.79 | 1154.01 | 1149.48 | 21.831 | 43.662 |
Retained Earnings (Accumulated Deficit) | 798.426 | 703.161 | 576.564 | 468.705 | 443.984 |
Total Liabilities & Shareholders’ Equity | 2213.97 | 2128.05 | 1913.28 | 665.9 | 659.973 |
Total Common Shares Outstanding | 100.982 | 98.0196 | 98.0196 | 83.7196 | 83.7196 |
Goodwill, Net | 171.517 | 149.227 | 5.3 | 5.3 | 5.3 |
Current Port. of LT Debt/Capital Leases | 11.1 | 8.9 | 8.2 | 7.566 | |
Capital Lease Obligations | 10.4 | 20.7 | 17.254 | ||
Other Liabilities, Total | 64.005 | 99.093 | -0.037 | 5.633 |
Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
---|---|---|---|---|---|
Total Current Assets | 1834.53 | 1718.72 | 1922.49 | 1797.48 | 1728.3 |
Cash and Short Term Investments | 1452.53 | 1369.57 | 1580.82 | 1488.37 | 1402.41 |
Cash & Equivalents | 1452.53 | 1369.57 | 1580.82 | 1488.37 | 1402.41 |
Other Current Assets, Total | 382.002 | 349.159 | 341.664 | 16.841 | 325.89 |
Total Assets | 2304.25 | 2157.08 | 2324 | 2213.97 | 2161.37 |
Property/Plant/Equipment, Total - Net | 208.776 | 178.091 | 152.293 | 157.725 | 163.321 |
Goodwill, Net | 177.906 | 178.059 | 170.084 | 171.517 | 182.343 |
Intangibles, Net | 46.172 | 46.154 | 46.128 | 46.075 | 46.409 |
Long Term Investments | 28.065 | 28.065 | 25.842 | 25.843 | 25.845 |
Other Long Term Assets, Total | 8.804 | 7.982 | 7.17 | 15.325 | 15.154 |
Total Current Liabilities | 217.488 | 217.764 | 186.275 | 164.991 | 173.367 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 217.488 | 217.764 | 186.275 | 43.896 | 173.367 |
Total Liabilities | 318.982 | 273.271 | 237.137 | 241.55 | 312.53 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Deferred Income Tax | 13.274 | 13.29 | 12.532 | 12.552 | 14.166 |
Minority Interest | 0.002 | 0.002 | 0.002 | 0.002 | 0.002 |
Other Liabilities, Total | 88.218 | 42.215 | 38.328 | 64.005 | 124.995 |
Total Equity | 1985.27 | 1883.81 | 2086.87 | 1972.42 | 1848.84 |
Other Equity, Total | 1985.27 | 1883.81 | 2086.87 | 1972.42 | 1848.84 |
Total Liabilities & Shareholders’ Equity | 2304.25 | 2157.08 | 2324 | 2213.97 | 2161.37 |
Total Common Shares Outstanding | 100.982 | 100.982 | 100.982 | 100.982 | 100.982 |
Total Receivables, Net | 149.436 | ||||
Accounts Receivable - Trade, Net | 130.703 | ||||
Total Inventory | 142.838 | ||||
Accounts Payable | 32.05 | ||||
Accrued Expenses | 77.945 | ||||
Current Port. of LT Debt/Capital Leases | 11.1 | ||||
Capital Lease Obligations |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Net income/Starting Line | 361.459 | 253.737 | 228.15 | 242.511 | 277.359 |
Cash From Operating Activities | 318.943 | 221.875 | 221.256 | 147.855 | 183.12 |
Cash From Operating Activities | 23.89 | 27.241 | 20.53 | 15.593 | 7.546 |
Non-Cash Items | -9.103 | 0.047 | -3.709 | 3.075 | 0.591 |
Cash Taxes Paid | 54.91 | 55.934 | 72.092 | 72.292 | 52.408 |
Cash Interest Paid | 0.694 | 0.401 | |||
Changes in Working Capital | -57.303 | -59.15 | -23.715 | -113.324 | -102.376 |
Cash From Investing Activities | -18.141 | -126.967 | -16.075 | -39.024 | -47.301 |
Capital Expenditures | -17.916 | -6.379 | -16.075 | -39.024 | -13.454 |
Other Investing Cash Flow Items, Total | -0.225 | -120.588 | 0 | -33.847 | |
Cash From Financing Activities | -313.588 | -81.846 | 1051.4 | -181.09 | -158.728 |
Total Cash Dividends Paid | -301.331 | -68.87 | -65.012 | -173.365 | -156.028 |
Issuance (Retirement) of Stock, Net | -0.214 | 4.525 | 1126.84 | ||
Foreign Exchange Effects | 16.472 | 3.735 | -2.525 | 1.128 | 2.015 |
Net Change in Cash | 3.686 | 16.797 | 1254.05 | -71.131 | -20.894 |
Financing Cash Flow Items | -2.9 | -2.8 | -2.8 | -3.2 | -2.7 |
Issuance (Retirement) of Debt, Net | -9.143 | -14.701 | -7.632 | -4.525 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | 147.998 | 361.459 | 290.333 | 196.598 | 95.295 |
Cash From Operating Activities | 98.434 | 318.943 | 227.624 | 180.355 | 93.065 |
Cash From Operating Activities | 6.519 | 23.89 | 17.25 | 12.131 | 6.049 |
Non-Cash Items | -0.044 | -9.103 | -12.048 | -12.63 | -1.136 |
Cash Taxes Paid | 34.995 | 54.91 | 56.67 | 35.943 | 17.512 |
Changes in Working Capital | -56.039 | -57.303 | -67.911 | -15.744 | -7.143 |
Cash From Investing Activities | -1.332 | -18.141 | -18.433 | -13.896 | -5.081 |
Capital Expenditures | -1.279 | -17.916 | -18.433 | -13.896 | -5.081 |
Cash From Financing Activities | -3.36 | -313.588 | -310.977 | -305.541 | -2.211 |
Financing Cash Flow Items | 0 | -2.9 | -2.9 | 0 | 0 |
Total Cash Dividends Paid | 0 | -301.331 | -301.331 | -301.331 | 0 |
Issuance (Retirement) of Stock, Net | -0.417 | -0.214 | -0.206 | -0.206 | -0.206 |
Issuance (Retirement) of Debt, Net | -2.943 | -9.143 | -6.54 | -4.004 | -2.005 |
Foreign Exchange Effects | -1.286 | 16.472 | 19.515 | 10.746 | 1.24 |
Net Change in Cash | 92.456 | 3.686 | -82.271 | -128.336 | 87.013 |
Other Investing Cash Flow Items, Total | -0.053 | -0.225 | 0 | 0 | 0 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Biogaia Company profile
About BioGaia AB
Biogaia AB is a Sweden-based healthcare company that is engaged in the development and sell of probiotic products. The Company develops, markets and sells probiotic products with documented health benefits. The products are primarily based on different strains of the lactic acid bacterium Limosilactobacillus reuteri. The Company’s activities are divided into three segments: The Paediatrics segment drops, gut health tablets, oral rehydration solution (ORS) and cultures to be used as ingredients in licensee products; The Adult Health segment (gut health tablets, oral health lozenges and cultures as an ingredient in a licensee’s dairy products) and the Other (royalties in respect of development projects, revenue from packaging solutions in the subsidiary CapAble, etc.). The Company operates worldwide.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, BioGaia AB revenues increased 5% to SEK785.1M. Net income increased 9% to SEK196.3M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net income benefited from Other operating expenses/operating incom decrease from SEK17.4M (expense) to SEK11.2M (income). Dividend per share increased from SEK6.82 to SEK7.26.
Industry: | Biopharmaceuticals |
Kungsbroplan 3
STOCKHOLM
STOCKHOLM 112 27
SE
Income Statement
- Annual
- Quarterly
News
A way forward: a roundup of recent central bank decisions
Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.
12:47, 22 March 2024Bank of Japan Preview: will the BOJ end negative interest rates?
The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.
08:44, 18 March 2024Higher CPI leaves traders unfazed as US equities continue to build momentum
The latest US CPI reading hasn’t gone how the Federal would have hoped. Consumer prices came in higher than expected in February for the third month in a row.
12:42, 15 March 2024Four reasons why Bitcoin is surging to record highs
Bitcoin has surged to record highs. We discuss the four factors pushing Bitcoin higher and analyse the technicals of the cryptocurrency’s technicals.
10:18, 14 March 2024China’s National People’s Congress: The markets have again been left wanting more
China’s National People’s Congress (NPC) is underway, and the markets have so far been disappointed by what’s been delivered by the country’s central government. We look at some of the significant takeaways from the event, discuss China’s current economic conditions, and analyse the China A50.
08:23, 8 March 2024Central Banks: which one will cut first?
Central banks dominate the calendar in March and markets try to anticipate which one will be the first one to cut
13:14, 6 March 2024Nvidia (NVDA) confronts high expectations for Q4 results
Nvidia is arguably the hottest company on the planet. The company reports its Q4 results after the closing bell on Wednesday, the 21st of February. We preview what to expect from Nvidia’s earnings and analyse the technicals of its stock price.
12:13, 20 February 2024People also watch
Still looking for a broker you can trust?
Join the 580.000+ traders worldwide that chose to trade with Capital.com